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Chemerin [RARRES2 [retinoic acid receptor responder 2], TIG2 [tazarotene induced gene
2 (TIG2)]] is a multifunctional cytokine initially described in skin cultures upon exposure
to the synthetic retinoid tazarotene. Its secreted pro-form, prochemerin, is widely
expressed, found systemically, and is readily converted into active chemerin by various
proteases. Subsequent studies elucidated major roles of chemerin as both a leukocyte
chemoattractant as well as an adipokine. Chemerin’s main chemotactic receptor, the
G-protein coupled receptor CMKLR1, is expressed on macrophages, dendritic, and NK
cells. With respect to its role in immunology, chemerin mediates trafficking of these cells
to sites of inflammation along its concentration gradient, and likely helps coordinate early
responses, as it has been shown to have antimicrobial and angiogenic properties, as
well. Recently, there has been mounting evidence that chemerin is an important factor
in various cancers. As with its role in immune responses—where it can act as both a
pro- and anti-inflammatory mediator—the potential functions or correlations chemerin
has in or with cancer appears to be context dependent. Most studies, however, suggest
a downregulation or loss of chemerin/RARRES2 in malignancies compared to the normal
tissue counterparts. Here, we perform a comprehensive review of the literature to date
and summarize relevant findings in order to better define the roles of chemerin in the
setting of the tumor microenvironment and tumor immune responses, with an ultimate
focus on the potential for therapeutic intervention.
Keywords: chemerin, RARRES2, CMKLR1, CCRL2, GPR1, cytokine, chemoattractant, cancer

INTRODUCTION
Chemerin [also known as retinoic acid receptor responder 2 (RARRES2) or tazarotene induced
gene 2 (TIG2)] is a multifunctional, chemoattractant protein known for its roles in adipogenesis,
angiogenesis, skin function, metabolic activity, and, recently, tumorigenesis. Initially secreted
by the liver and white adipose tissue as prochemerin, the 163-amino acid precursor protein is
readily cleaved by a specific set of serine proteases to become a chemotactically-active protein
isoform of chemerin (1). Depending on the site of cleavage and subsequent interaction with its
cognate heptahelical receptors, CMKLR1 (chemokine-like receptor 1), CCRL2 (C-C chemokine
receptor-like 2), and GPR1 (G protein-coupled receptor 1), chemerin may exhibit varying degrees
of bioactivity and elicit pro- or anti-inflammatory effects in different biological environments (1–3).
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In the literature, CMKLR1 is usually discussed as the primary
receptor for chemerin interaction, while CCRL2 is described
to participate in various functions by binding and presenting
chemerin in a non-signaling manner to establish concentration
gradients (4, 5). On the other hand, GPR1 is less-well
characterized and found in the central nervous system (5) and
reproductive organs (6, 7) and may play a role in metabolism (8).
Since its initial discovery in skin cultures upon stimulation
with anti-psoriatic synthetic retinoid tazarotene, chemerin has
been further described in a number of biological settings
(9). In human endothelial cells, chemerin has been found
to mediate angiogenesis via interactions with CMKLR1 (10),
while, in the epidermis, chemerin has been shown to engage
in significant antimicrobial activity (11). Moreover, chemerin
has been linked with conditions such as obesity and diabetes,
where it may modulate metabolism and adipocyte development
(12, 13). Most recently, chemerin has been shown to mediate
the chemoattraction of various immunocytes in the tumor
microenvironment, while expression of chemerin’s receptors,
CMKLR1 and CCRL2, has been identified on a number of
leukocyte subsets, namely, dendritic cell subsets, natural killer
cells, and macrophages (1, 2, 14, 15). With recent findings that
chemerin’s receptors are also expressed on malignant tumor cells
and that chemerin’s expression is often altered in different cancer
types, newer studies have focused on chemerin’s novel roles in
immune surveillance and tumor progression.
As expected, these recent studies have confirmed the notion
that chemerin’s functions in cancer are context driven. In some
cancer types [e.g., glioblastoma, mesothelioma, neuroblastoma,
squamous cell carcinoma of the esophagus, and squamous cell
carcinoma of the oral tongue (SCCOT)], chemerin is upregulated
(16–22). In most cancer types [e.g., acute myeloid leukemia
(AML), adrenocortical carcinoma (ACC), breast cancer, Ewing
sarcoma, hepatocellular carcinoma, melanoma, non-small cell
lung cancer (NSCLC), prostate cancer, and squamous cell
carcinoma of the skin] chemerin is downregulated, likely via
hypermethylation of RARRES2 (15, 19, 23–28) (Table 1). Adding
to this complexity, the ultimate effects on tumor growth are
also context-dependent; both tumor suppression and accelerated
growth have been observed as a result of altered chemerin
expression levels (Table 2). Thus, in this review, we attempt to
catalog and analyze chemerin’s specific functions in each tumor
type, with a focus on identifying patterns in its mechanism of
action and suggesting ways in which the chemerin system may
be utilized or manipulated for clinical benefit.

TABLE 1 | Alterations of chemerin expression profiles by cancer type.
Cancer type:

Acute myeloid leukemia

↓

Adrenocortical carcinoma

↓

Breast cancer

↓

Colorectal cancer

Serum levels of
chemerin

↑
↑

Ewing sarcoma

↓

Gastric cancer

↑

↑

Glioblastoma
Hepatocellular carcinoma

↓

Melanoma

↓

Mesothelioma

↑

Neuroblastoma

↑

Non-small cell lung cancer

↓

Prostate Cancer

↓

Squamous cell carcinoma of the
esophagus

↑

Squamous cell carcinoma of the oral
tongue

↑

Squamous cell carcinoma of the skin

↓

↑

↑

underlying an urgent need for improved methods of detection
that may enable earlier life-preserving treatment (36).
In light of this need, chemerin has recently been identified
as a potential biomarker for diagnosis of AML. A study in 2017
revealed that chemerin was downregulated in the bone marrow
mononuclear cells of AML patients compared to that of healthy
controls, with ROC curve analysis showing a test specificity
of 79% (true positive) and sensitivity of 54% (true negative)
for chemerin expression as a marker for AML diagnosis. The
same group performed a cohort study of 149 patients, 32 of
whom had high chemerin expression and 117 of whom had
low expression, with no significant variability in certain gene
mutations, white blood cell count, platelets, and hemoglobin,
and found that patients with low chemerin expression correlated
with poorer overall survival. Moreover, multivariate analysis
on parameters such as age, various gene mutations, chemerin
expression, karyotypic classifications, and white blood cell count
verified that chemerin was independently able to prognosticate
AML patients, while univariate analysis of chemerin expression
levels showed that high chemerin expression was associated with
positive prognosis (22). In terms of chemerin receptor expression
levels (independent of associations between chemerin expression
and clinical outcome), a different group showed that CCRL2 was
overexpressed in AML, identifying the non-classically signaling
chemerin receptor as a potential therapeutic target, along with
other GPCRs that were also overexpressed (37).

CANCERS
Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is the most prevalent form of
acute leukemia affecting adults, with a particularly high rate of
incidence (12.2 cases per 100,000 people) for those above the age
of 65 (32–34). Though recent advances in AML treatments have
significantly improved prognosis for younger patients, those who
are older have little chance of survival (35). In fact, a majority of
AML patients over the age of 65 die within a year of diagnosis,
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Tumor expression
of chemerin

Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is an extremely rare and
aggressive tumor that is associated with poor prognosis in
patients. The incidence rate for ACC is 0.7–2.0 cases per million
people per year, and for patients that undergo first-line treatment
(surgical resection), the 5-year median survival rate is 38.6%. For
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patients ineligible or unwilling to undergo adrenalectomy, there
is little chance of remission (38–40). In fact, the potential risk
of ACC is considered the standard for adrenalectomy in patients
with adrenal incidentalomas (38).
Recent research suggests that serum chemerin levels have
prognostic value in ACC and that manipulating chemerin
levels in ACC tumors may prove efficacious in ACC patients.
Chemerin’s role as a chemoattractant, in recruiting immune cells
to sites of inflammation, has already been well documented;
for instance, chemerin has been shown to suppress neoplasia
by eliciting natural killer cells to the tumor site in melanoma
(15). In line with those findings, a study by Chittenden
et al. (28) featuring a group of 20 ACC patients, 53 benign
tumor patients, and 21 healthy individuals reported that
serum chemerin levels were elevated in ACC patients as
compared to those with benign adrenocortical tumors, and
the difference further increased when tested against healthy
controls. They also discovered that higher serum chemerin levels
were strongly associated with better overall survival. Though
seemingly paradoxical, it was proposed that two important,
proven factors may explicate this phenomenon. First, a mouse
xenograft model showed that increased serum chemerin levels
were not a result of secretions from the tumor itself but from
the host environment (28). Second, as mentioned previously,
chemerin has been shown to be an effective recruiter of immune
cells to sites of inflammation (1, 14, 15, 41). Thus, it was
suggested that ACC may downregulate chemerin as a method
of immune evasion and that the host environment may increase
secretion of chemerin in serum as a counteractive response
(28).
Interestingly, in addition to the potential for immunedependent methods of tumor suppression, a new study has found
evidence that chemerin may directly alter malignant cells in
an immune-independent manner. A study by Liu-Chittenden
et al. (42) found that the RARRES2 gene was transcriptionally
downregulated in ACC, in line with similar findings in other
cancer types. Specifically, the silenced RARRES2 gene in ACC
tumors was characterized by hypermethylation at five CpG
sites. This was confirmed in three human ACC cell lines and
HEK293 cells via treatment with a DNA methyltransferase
inhibitor, which showed that such treatment reversed the
effects of methylation at all CpG sites in a dose dependent
manner (42, 43). [As an aside, in Ewing sarcoma, a rare,
malignant tumor that grows inside the bones and in nearby
soft tissues, RARRES2 showed a high rate of methylation and
was one of only eight genes to have a frequency of silencing
>20% (25). Thus, hypermethylation of RARRES2 is likely a
common method of gene silencing in tumors where chemerin is
downregulated].
When ACC cell lines were transfected to express chemerin,
significant inhibition of tumor growth was observed in a
dose dependent manner, as the cell lines that had higher
expression of chemerin correlated to a more compelling
reduction in tumorigenesis (42). Supporting these results,
exogenous addition of recombinant chemerin in vitro showed
no meaningful effect in affecting cell proliferation among
various ACC cell lines, implying that the mechanism of growth
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inhibition was not mediated by the binding of chemerin
to its receptors, such as CMKLR1 (42). In fact, chemerin’s
function in reducing ACC tumor growth was found to be
mediated by two different, immune-independent mechanisms.
First, chemerin overexpression could induce β-catenin
phosphorylation, and thus, proteasome mediated degradation.
In phosphokinase arrays of a chemerin overexpressing ACC
cell line, significant reduction in total β-catenin levels was
observed, whereas treatment with a proteasome inhibitor
prevented proteasome mediated degradation, allowing for
detection of elevated phosphorylated β-catenin levels (42).
The phosphorylated sites were identified as Ser33, Ser37, and
Thr41. Consequently, a decrease in Wnt/β-catenin pathway
activity was observed and confirmed via a TCF/LEF luciferase
reporter assay (42). Second, chemerin overexpression could
inhibit p38 MAPK phosphorylation. The phosphokinase
array, which showed a decrease in total β-catenin levels,
also showed a reduction in phospho-p38 MAPK levels (42).
In vivo xenograft studies in athymic nude mice and NSG
mice, both immunodeficient mouse models, confirmed that
chemerin overexpression resulted in lower β-catenin and
phosphorylated p38 MAPK levels (42). Together, these results
indicated that chemerin could promote tumor suppression
through immune-independent pathways, both in vitro and in
vivo.
These findings may have positive implications for ACC
patients and other cancer patients alike. β-catenin (CTNNB1),
a proto-oncogene, is frequently mutated in ACC, resulting in
constitutive activation of the Wnt/β-catenin pathway (44). The
occurrence of activating mutations of CTNNB1 is generally
known to be a significant pathway for ACC tumorigenesis.
Indeed, a majority of adrenocortical tumors exhibit activation
of the Wnt/β-catenin pathway, which is correlated with poor
outcomes in ACC patients (45, 46). Aberrant activation of the
Wnt/β-catenin pathway is common in many other cancer types,
such as breast cancer, lung cancer, hepatocellular carcinoma, and
squamous cell carcinoma (47). Additionally, elevated phosphop38 MAPK levels are found in a majority of adrenocortical
tumors (42). In other cancer types such as lung cancer and
colon cancer, abnormal activation of p38 signals are detected
(48, 49). As such, it is reasonable to suspect that chemerin
may have similar, tumor-suppressive effects in other cancer
types.
Finally, chemerin may also serve as a prognostic marker for
ACC. Among patients, tissue chemerin levels did not correspond
to prognosis, though chemerin expression was downregulated
in ACC tissue samples (28). However, serum chemerin levels
did correspond to prognosis. A clinical survey showed that
serum chemerin levels were significantly elevated in ACC
patients in comparison to patients with benign tumors and
even more so in comparison to healthy controls. Survival
analysis of median serum chemerin levels in ACC patients
determined that higher serum chemerin levels correlated with
longer survival. Moreover, prognosis for patients with recurrent
ACC could be stratified according to varying serum chemerin
levels, further verifying its value as a marker for ACC prognosis
(28).
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TABLE 2 | Mechanisms of chemerin-mediated effects by cancer type.
Cancer type

Model

Technique/method

Results

Chemerin-mediated effect

Adrenocortical
Carcinoma (28)

HEK293, H295R

BioCoat Matrigel
invasion/migration assays

Transient overexpression of chemerin inhibited
cell proliferation in HEK293, while inhibiting
cellular invasion in KEK293, H295R

Inhibition of tumor cell proliferation
and invasion

H295R

Phosphokinase array
+Western blot analysis

Phosphorylation and subsequent degradation
of β-catenin and inhibition of p38 MAPK
phosphorylation observed in stable,
chemerin-overexpressing H295R ACC cell lines

Reduced β-cateinin and
phosphorylated p38 MAPK levels

H295R,
HumanACC
Tumor Samples

TCF/LEF Luciferase
Reporter Assay +
Immunohistochemistry

TCF/LEF reporter activity reduced in
chemerin-overexpressing ACC cell lines
compared to vector cell line; nuclear localized
phosphorylated p38 signals detected in a
majority of ACC tumor samples

Decreased activity of Wnt/ β-catenin
and MAPK pathways

Athymic Nude
Mice, NSG Mice +
H295R

Subcutaneous inoculation
ofH295R in Athymic nude +
NSG mice

Overexpression of chemerin significantly
impaired tumor growth and resulted in lower
tumor weight in both mouse models

Suppression of tumor growth

AGS, MKN28

Matrigel-coated Transwell
assay

Increased invasion of AGS and MKN28 cells
through Matrigel-coated Transwells at
extremely low concentrations (0.0 I ng/ml)

Enhanced tumor invasion

AGS, MKN28

Real time-PCR

Induction of mRNA expression of pro-invasive
genes, IL-6, VEGF, via chemerin in AGS and
MKN28, and also MMP-7 in MKN28

Increased expression of IL-6, VEGF,
MMP-7

AGS, MKN28

Western blot analysis

Increased phosphorylation of p38, ERKl/2 via
chemerin in AGS, MKN28

Increased activity of MAPK pathways
(MEK-ERK, MKK3/6-p38)

Glioblastoma (17)

U87MG

Calcium mobilization assay

Chemerin stimulation induced a transient, dose
dependent increase of intracellular calcium in
U87 MG cells

Induction of intracellular calcium

Hepatocellular
Carcinoma

C57BL/6 Mice
+Hepal-6

Implantation of HCC
hepal-6 in C57BL/6 mice +
subcutaneous model

WT mice with chemerin-expressing Hepa 1-6
tumors had a lower mortality rate and liver
tumor growth/weight compared to Rarres2−/−
mice with Hepa1-6 tumors

Inhibition of tumor growth

C57BL/6 Mice
+Hepa1-6

Intravenous injection of
hepal-6 in C57BL/6 mice

WT mice with chemerin-expressing Hepa1-6
tumors had less metastatic nodules compared
to Rarres2−/− - mice with Hepal-6 tumors

Reduced lung metastasis

C57BL/6 Mice
+Hepa1−6

Flow cytometry

Rarres2−/− mice with Hepa1-6 tumors
showed heightened proportions of MDSCs and
TAMs and decreased levels ofCD4/CD8 T cells
compared to WT mice with
chemerin-expressing Hepal-6

Reduced induction of MDSCs and
TAMs and increased accumulation of
tumor infiltrating CD4/CD8 T cells

C57BL/6 Mice
+Hepal-6

Quantitative reverse
transcriptase-PCR

Chemerin-expressing Hepal-6 tumor cells
exhibited significantly decreased expression
ofGM-CSF, IL-6

Reduced expression of GM-CSF +
IL-6

7404, HepG2

Boyden chamber +
Transwell invasion assay

Overexpression of chemerin resulted in reduced
migratory ability and invasiveness of 7404 cells,
whereas chemerin knockdown enhanced these
properties in 7404/che Hand Hep G2 cells

Reduced migratory ability and
invasiveness

BALB/c Mice
+PVTT-1

Left ventricular +
intrahepatic injection model

Prolonged survival and reduced/delayed
appearance of metastatic foci was observed in
mice injected with PVTT−1 che cells (chemerin
overexpressing), compared to mice injected
with PVTT−1 con cells in both injection models
(Resuts were replicated by regularly injecting
chemerin in mice with PVTT-1 tumors)

Inhibited metastasis and prolonged
survival times (Reduced weight loss)

Gastric Cancer
(29)

Li et al. (30)

(Continued)
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TABLE 2 | Continued
Cancer type

Melanoma (15)

Neuroblastoma
(21)

Non-Small Cell
Lung Cancer (31)

Squamous Cell
Carcinoma of the
Esophagus (20)

Squamous Cell
Carcinoma of the
Skin (19)

Model

Technique/method

Results

Chemerin-mediated effect

HCCTMA

Immunohistochemistry

High levels of chemerin were correlated with
low levels of p-Akt (Ser473) and high levels of
PTEN in HCC TMA

Reduced Akt/MMP 1 as a result of
positive regulation of PTEN via
chemerin

7404, PVTT-1,
Hep3B, HepG2

Western blot analysis

In chemerin-overexpressing HCC cells (7404,
Hep3B, and PVTT-1), reduced p-Akt(Ser473)
levels were observed, while elevated
p-Akt(Ser473) levels were observed in
chemerin knockdown HCC cells (7404/che H,
HepG2)

Downregulation ofp-Akt (Ser473)

C57BL/6 Mice
+Bl6

Flow cytometry

The average frequency of NK and T cells were
increased in chemerin- expressing tumors

Enhanced infiltration of antitumor
leukocytes

C57BL/6 Mice
C57BL/6 Mice

Subcutaneous inoculation
ofB16 murine melanoma in
C57BL/6 Mice

Chemerin-expressing melanomas exhibited
delayed growth compared to control
transfectants (measured by tumor size)

Impaired tumor growth

SK-N-SH

Confocal laser scanning
microscopy

Fast, transient increase in intracellular calcium
observed in SK-N-SH cells following
stimulation with lOnM chemerin

Induction of intracellular calcium

SK-N-AS,
SK-N-BE(2)

Western blot analysis

Increased, dose dependent phosphorylation of
Akt, MEKl/2, ERKl/2 in cell lines observed after
stimulation via chemerin

Increased activity of MAPK and Akt
pathways

SK-N-AS,
SK-N-BE(2)

Real-time zymography

Increased synthesis ofMMP-2 in cell types after
6, 12, 24, 48 h stimulation with chemerin

Increased expression of MMP-2

LLCI

Flow cytometry

Splenocytes cultured with
prochemerin-expressing Lewis Lung Cancer
cells (LLC) exhibited decreased levels ofTNF-a,
IL-12 p40 and slightly increased levels of IFN-y

Decreased expression of
inflammatory cytokines, TNF-a, IL-12
p40

C57BL/6 Mice
+LLCI

Subcutaneous inoculation of
Prochemerin-LLCI into
C57BL/6 mice

C57BL/6 mice with prochemerin-expressing
LLC tumors exhibited a lower incidence of
tumor formation, but not a decrease in tumor
growth rate

Prochemerin induced inhibition of
tumor formation

OE21

Matrigel-coated boyden
chamber invasion assay

Enhanced invasion of OE21 cells in
Matrigel-coated Boyden chambers upon
stimulation with chemerin (effects abrogated by
CCX832, a CMKLRI inhibitor)

Enhanced tumor invasion

OE21

Western blot analysis

Increased expression of MMP-1, MMP-2,
MMP-3 in OE21 cells stimulated by
myofibroblast-secreted chemerin (effect
mediated by protein kinase C; MMP responses
inhibited by Ro31822, a PKC inhibitor)

Increased expression of MMP-l,
MMP-2,MMP-3

OE21

Enzyme activity assay

Increased activity ofMMP-1, MMP-2, MMP-3
(measured in fluorescence intensity) in OE21
cell media, induced by chemerin

Increased activity of MMP-1, MMP-2,
MMP-3

SCL-1,
SCC-12B2,
SCC-13, A431

Transwell Chamber
Migration assay

Significant increase in cell migration (cells/HPF)
induced by I 0, 20, 40 nM of recombinant
human chemerin (SCL-1), 20,40 nM
(SCC-12B2), 10, 20, 40 nM (SCC-13), 20 nM
(A431)

Enhanced tumor migration

SCL-1

GPCR Cignal Finder array

Enhanced MAPK activity of JNK and ERK
signaling pathways after I hour of stimulation
via recombinant human chemerin

Increased activity of MAPK pathways
(JNK, ERK)

SCL-1

Western blot analysis

Increased phosphorylation of ATF2, c-Jun,
SEK1, ERKI/2 observed in chemerin treated
SCL-1 cells compared to untreated SCL-1 cells

Increased activity of MAPK pathways
(JNK, ERK)

Frontiers in Immunology | www.frontiersin.org

5

November 2018 | Volume 9 | Article 2772

Shin et al.

Chemerin in Cancer

Breast Cancer

properties, it was proposed that chemerin may play a role in
modulating gut microbial activity, which may play a role in
the various bowel symptoms affecting colorectal cancer patients
(11, 60). Supporting this hypothesis, colorectal cancer patients
who have undergone resection surgery have consistently reported
altered gut microbial activity, which has been linked to numerous
bowel symptoms in these patients (61–63). Interestingly, the gut
microbiome is somewhat altered in chemerin KO mice compared
to WT controls, with an increase in Desulfovibrionaceae (64).
Increases in this pathobiont have been reported as a component
of IBD-associated gut dysbiosis (65).

Breast cancer is the most common malignancy in women,
accounting for a quarter of all cancer cases in females (50).
It is estimated that one in every eight women will develop
breast cancer at some point in their lives (51). In this context,
chemerin has not been deeply investigated; though, there are
some preliminary pieces of evidence showing that chemerin is
significantly downregulated in breast adenocarcinomas, one of
the most common forms of breast cancer (15). Additionally,
studies have detected CMKLR1 in breast tissue (52). Taken
together, these facts raise the suspicion that chemerin may exhibit
antitumor effects in breast cancer.
However, pro-tumor effects are also possible. Given the
increased risk of breast cancer due to post-menopausal obesity
and chemerin’s known associations with obesity and obesity
related parameters, such as blood pressure and BMI, some
suspect that chemerin may be correlated to higher risk of
breast cancer, albeit indirectly (51, 53). Moreover, it has been
experimentally shown that some adipose-derived angiogenic
factors may promote breast cancer growth, though this remains
to be tested in the context of chemerin (54, 55). It has also been
speculated that chemerin may play a role in instigating metastasis
through its angiogenic functions (51). For prognosis, it is unclear
whether chemerin can be used as a biomarker for breast cancer. A
cross sectional study involving 117 breast cancer patients by Akin
et al. (51) showed that serum chemerin levels could not be used
in staging of breast cancer, as there were no differences in serum
chemerin levels of patients with metastatic and non-metastatic
cancer.

Gastric Cancer
Gastric cancer is the fourth most common cancer and the second
most common cause of cancer-related death in the world (66).
Treatment of gastric cancer generally consists of a combination
of surgery and chemotherapy (66). Though current clinical
parameters for diagnosis are incapable of accurately predicting
patient outcomes, recent evidence has revealed chemerin’s
prognostic value in gastric cancer, as well as its functions in tumor
growth (67).
A 2014 study comparing 196 gastric cancer patients with 196
age- and sex-matched healthy controls showed that preoperative
plasma chemerin levels were significantly elevated in cancer
patients (67). Multivariate analysis of clinical parameters
currently used for diagnosis and serum chemerin levels showed
that serum chemerin could be used as an independent predictor
of 5-year mortality, 5-year adverse event, overall survival, and 5year disease free survival, though further research is needed to
adjust for the possibility of postoperative alterations (67).
In terms of functional roles, studies have shown that
chemerin exhibits pro-tumor effects in gastric cancer, confirming
the notion that chemerin’s pro/anti-tumor functions are
context dependent. Indeed, elevated serum chemerin levels
were observed in gastric cancer patients and were shown
to be correlated with increased tumor invasiveness (29).
Specifically, chemerin contributed to tumor growth by inducing
phosphorylation of p38 and ERK 1/2 MAPKs and upregulating
IL-6, MMP-7, and VEGF (29). Chemerin treatment did not alter
the in vitro proliferation of two human gastric cancer cell lines,
AGS and MKN28. However, chemerin increased the invasiveness
of both cell types through Matrigel-coated transwells with only
miniscule concentrations of chemerin. In fact, the number of
cells invading through the membrane increased fivefold or more
for AGS and MKN28 cells exposed to chemerin. Moreover,
chemerin increased mRNA expression of VEGF and IL-6 in AGS
and MKN28 cells, while also increasing expression of MMP-7
exclusively in MKN28 (29). VEGF, IL-6, and MMP-7 have all been
associated with enhanced tumor invasiveness in gastric cancer
(68–70), while high expression of VEGF and IL-6 have been
shown to stimulate metastasis of malignant cells and indicate
poor clinical outcomes in gastric cancer patients, suggesting a
potential impact of chemerin in this setting (69–72).
In addition to increased expression of various pro-invasion
genes, stimulation of AGS and MKN28 via chemerin resulted
in elevated phosphorylation of p38 and ERK1/2 in both cancer
lines, suggesting that chemerin could activate MKK3/6-p38

Colorectal Cancer
Colorectal cancer has the third highest incidence rate and fourth
highest mortality rate of all cancers types, with 1.4 million
new cases and 700,000 related deaths per year (56). Current
treatment methods range from chemotherapy (e.g., single-agent
5-fluorouracil, oxaliplatin, and/or irinotecan) to other regimens
consisting of newer, targeted substances, such as anti-vascular
endothelial growth factor-A antibodies or anti-epidermal growth
factor receptor antibodies (57).
Among the early diagnostic tools that have become available
in recent years, serum chemerin levels have been identified as
an effective biomarker for colorectal cancer. A study in 2018
compared 32 colorectal cancer patients with sex, BMI, and age
matched healthy volunteers and reported that chemerin was
significantly upregulated in serum of colorectal cancer patients,
increasing with higher tumor stage progression (58). The area
under the receiver operating characteristic (ROC) curve for
serum chemerin levels was 1, with a sensitivity and specificity
of 100% (58). The results clearly indicated that serum chemerin
could be an effective biomarker for colorectal cancer and stage
progression.
Additionally, a pilot study of 110 colorectal cancer survivors
in Korea showed that there was an inverse relationship between
serum chemerin levels and colorectal cancer-related quality
of life, defined in terms of Functional Assessment of Cancer
Therapy (FACT)-General, -Colorectal, and -Fatigue scores (59).
Given that chemerin has been shown to have antimicrobial
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and infiltration of dendritic cells and natural killer cells.
Additionally, chemerin was identified as an independent factor
for prognosis via multivariate analysis, with lower chemerin
expression corresponding to poorer overall survival (23).
A later study by Lin et al. (82) further reported that chemerin
could inhibit HCC tumor growth. In an orthotopic mouse
model of HCC, chemerin knockout mice showed aggressive
tumor growth and metastasis. In contrast, overexpression of
chemerin in mice resulted in delayed tumor growth, suggesting
that chemerin may hamper tumor progression. Specifically,
the inhibitory effect was mediated by suppressing pro-tumor
inflammatory cytokines. When Hepa1-6 cells were treated
with chemerin in vitro, cell survival and proliferation was
unaffected. Moreover, chemerin knockout mice with accelerated
tumor growth exhibited increased expression of granulocytemacrophage colony-stimulating factor (GM-CSF) and IL-6 and
accumulation of myeloid-derived suppressor cells (MDSCs) and
tumor-associated macrophages (TAMs). Neutralization of GMCSF and IL-6 reversed the effects in the chemerin knockout mice,
showing that these two cytokines were mainly responsible for the
accelerated growth. Combined with the fact that serum chemerin
levels were inversely correlated to GM-CSF and IL-6 expression
levels in patients with HCC, the study suggested that chemerin
may have a negative regulatory role for these two cytokines (82).
Further verifying these claims, chemerin was shown to
inhibit nuclear factor-κB activation, an important factor for
GM-CSF and IL-6 expression (83, 84). The data consistently
showed that chemerin targeted tumor cells and tumor-associated
endothelial cells, the major source of GM-CSF and IL-6, via
interaction with CMKLR1 and CCRL2, reducing expression of
inflammatory cytokines and inhibiting NF-κB activation (82).
Downregulation of CMKLR1 and CCRL2 via siRNA in Hepa1-6
cells reestablished GM-CSF and IL-6 expression, indicating that
decreased expression of the cytokines was mediated by chemerinCMKLR1/CCRL2 interactions. The observed consequences of
reduced GM-CSF and IL-6 expression were impaired MDSC
accumulation, reestablishment of anti-tumor IFN-γ+ T-cell
activity, and hampered tumor angiogenesis (82).
The inhibitory function of chemerin in HCC was mediated
by both T-cell dependent and independent mechanisms. Because
chemerin showed less of an inhibitory effect in Rag1 knockout
and CD8-T-cell depleted mice, it was determined that chemerin’s
function in HCC was not completely based on T-cell anti-tumor
activity (82). It was postulated that chemerin’s T-cell independent
mechanism of inhibition was mediated by reduced accumulation
of MDSCs, which are a major source of pro-angiogenic factors
Bv8 and MMP-9. Supporting this hypothesis, overexpression of
chemerin in mice resulted in a notable decrease in Bv8 and
MMP-9 expression and, ultimately, tumor angiogenesis (82).
A recently published study showed a novel interaction of
chemerin and the tumor suppressor PTEN in a mouse model
of HCC (30). In vitro, overexpression of chemerin resulted
in reduced migratory ability and invasiveness of human HCC
line 7404. Chemerin knockdown, in turn, resulted in increased
migratory ability and invasiveness. In vivo, overexpression of
chemerin inhibited intra- and extrahepatic metastases of HCC
cells in nude mice, lengthening survival times of HCC inoculated

and MEK-ERK MAPK signaling cascades (29). Importantly,
these are known mechanisms by which tumor cells modulate
growth and invasion in gastric cancer (73–76). Elevation of
phosphorylated ERK 1/2 levels have been associated with poor
survival in patients, and p38 activation has been found to incite
peritoneal dissemination in gastric cancer (75, 76). Given that
these effects were abrogated by treatment with inhibitors of
MEK-ERK signaling, it was clear that the MEK-ERK MAPK
pathway was primarily associated with increased gastric cancer
invasiveness (29). Together, the results of the studies indicated
that chemerin may engender pro-tumor effects in gastric cancer,
while also serving as a marker for patient prognosis.

Glioblastoma
Glioblastoma is the most malignant form of brain tumors
affecting adults (77). Recent advances in glioblastoma research
have made new treatment methods available to patients, such as
tumor-treating fields and immunotherapy. However, the classical
approach to treating glioblastoma remains a multipronged
effort, using a combination of surgical resection, radiation, and
chemotherapy (77). The incidence rate of glioblastoma hovers
around 3.19 cases per 100,000 people in the United States and
is very uncommon in children (78).
Though chemerin’s role in glioblastoma is still unclear,
studies have reported an altered chemerin profile in glioblastoma
cases (17). First, one study found that chem158 K, a bioactive
isoform of chemerin, was elevated in the cerebrospinal fluid of
patients with malignant glioblastoma (79). A later study found
that chemerin mRNA expression was significantly increased in
grade 3 and 4 glioma, equivalent to malignant glioblastoma,
compared to epilepsy and grade 2 glioma (17). In contrast,
CMKLR1 and CCRL2 mRNA expression was unaltered in those
cases. To further test whether chemerin could function as a
signaling molecule, in vitro experiments were conducted using U87 MG cells, a human glioblastoma cell line. Experimental results
determined that the addition of chem157S, another bioactive
isoform of chemerin, to U-87 MG cells resulted in a transient,
dose-dependent increase of intracellular calcium, indicating that
chemerin could instigate intracellular signaling in U-87 MG cells
(17). Whether these results translate to experiments in vivo
remains to be seen.

Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most prevalent
cancer in the world, with more than 500,000 new cases being
diagnosed each year (80). It is mainly caused by chronic liver
damage due to hepatitis B or hepatitis C and is associated with
risk factors such as obesity and diabetes (80). Currently, a variety
of treatment options are available to patients, including liver
transplantation, curative resection, radiotherapy, radio/chemoembolization, and systemic therapies (81).
In recent years, chemerin has been identified as a potential
therapeutic agent for HCC. A study comparing chemerin
expression levels in 124 HCC patient tumors and matched,
normal tissues showed that chemerin was significantly
downregulated in 72 of the patients’ liver tissues and that
tissue chemerin expression correlated with tumor size, grade,
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suppression (89, 90). Moreover, chemerin’s tumor suppressive
effects in melanoma were mediated by NK cells, as their depletion
abrogated the antitumor effects, while a lack of T cells and B
cells did not alter the tumor growth-inhibition phenotype (15).
Further experiments showed that host expression of CMKLR1
was necessary for inhibited tumor growth, since chemerinexpressing mouse melanoma grew faster than control B16
tumors in CMKLR1-negative mice. Finally, local administration
of chemerin suppressed tumor growth in vivo (15).
Thus, in melanoma, chemerin was shown to inhibit tumor
growth by eliciting antitumor responses and altering the tumor
microenvironment in favor of growth inhibition. Whether
by tumoral expression or local administration, these tumorsuppressive effects could be observed in vivo (15). Additionally,
high expression of chemerin was shown to be associated
with better outcomes for patients in two clinical studies,
demonstrating chemerin’s potential for therapeutic intervention
in melanoma (15).

mice. Nude mice with chemerin overexpressing tumors showed
markedly less distant metastases and delayed appearance of
metastatic foci using control or chemerin-expressing PVTT-1
HCC cells. Consistent observations were made in an intrahepatic
injection model. Moreover, regular intraperitoneal injections
or intrahepatical injections of chemerin in mice with PVTT-1
tumors replicated these results, with the additional benefit of
reduced weight loss, showing that chemerin could potentially be
therapeutically administered to suppress HCC metastases.
Underlying these tumor suppressive effects, the mechanism
of reduced HCC cell migration and invasion via chemerin was
shown to be mediated by negative regulation of p-Akt (Ser473)
by PTEN. P-Akt and MMP-1 levels, as well as ubiquitination
of PTEN, were reduced in chemerin-overexpressing HCC cell
lines and elevated in chemerin-knockdown HCC cell lines.
PTEN levels were upregulated in chemerin-overexpressing HCC
cell lines and downregulated in chemerin-knockdown HCC
cell lines. Immunohistochemistry of HCC tissues showed that
upregulation of chemerin correlated with low p-Akt and high
PTEN levels. Supporting these findings in vivo, data from their
tumor models showed that overexpression of chemerin was
associated with reduced tumor MMP-1 and p-Akt levels, elevated
PTEN levels, and reduced metastases. Taken in aggregate, these
studies provided strong support for therapeutic applications of
chemerin in HCC.

Mesothelioma
Mesothelioma is a tumor that grows in the linings of various
organs, such as the lungs or the heart. Tumorigenesis is instigated
by exposure to specific, carcinogenic mineral fibers, namely
asbestos (63). Due to the commercial use of such materials,
the incidence of mesothelioma has increased over the years,
from near non-existence to several thousand cases per year (63).
Though treatments are available, such as chemotherapy with
cisplatin and pemetrexed, prognosis is still dismal and diagnosis
very difficult, as it may take several decades for symptoms
to appear (91). Regarding chemerin’s role in mesothelioma,
literature on the topic is scarce, though it was one of the first
identified cancer types where RARRES2 expression was altered
(significantly increased, compared to matched normal tissue)
(16). It remains unclear if chemerin contributes in any way to
mesothelioma progression.

Melanoma
Melanoma has one of the fastest growing incidence rates in the
world, which in the US has risen from 8.2–9.4 cases per 100,000
people in 1975 to 24.2–35.4 cases per 100,000 people in 2010 (85).
Unlike many malignancies, melanoma affects a diverse range of
age groups, with a median age of diagnosis of 57 years (86). It
is also widely recognized as the most aggressive form of skin
cancer, accounting for the majority of skin cancer-related deaths
vs. a fraction of total cases (86). Significantly, recent research
has elucidated chemerin’s ability to induce tumor suppression in
melanoma, where chemerin was found to be downregulated (15).
Our group previously identified the mechanism of tumor
suppression via chemerin in melanoma, showing that tumor
expression of chemerin led to inhibited tumor growth in
vivo. When chemerin-expressing B16F0 (hereafter, B16) cells
were implanted into mice, the mouse melanoma showed
significant delay in growth compared to control B16 cell
lines. Importantly, the RARRES2-transfected B16 cells expressed
bioactive chemerin, confirmed via chemotaxis, and both the
transfected line and control B16 lines lacked expression of
CMKLR1. When tested in vitro, chemerin treatment failed to
alter B16 cell proliferation, suggesting that chemerin’s inhibitory
effects in melanoma was mediated by host immune responses
(15). It was also noted that chemerin expressing tumors exhibited
enhanced infiltration by NK and T cells; ratios of NK and
T cells to MDSCs and/or plasmacytoid dendritic cells (pDC)
were also increased (15, 87, 88). Given that certain subsets
of pDCs and MDSCs have been reported to be tolerogenic,
suppressing the body’s antitumor immune responses, it was noted
that increased ratios of antitumor immune cells to tolerogenic
ones would translate to a more favorable environment for tumor
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Neuroblastoma
Neuroblastoma is a pediatric cancer affecting the sympathetic
nervous system. With <50% probability of cure for highrisk cases, the prognosis for children with advanced stage
neuroblastoma is bleak (92). For those with high-risk
neuroblastoma, treatment is intensive, consisting of several
modalities, such as chemotherapy, surgery, immunotherapy,
stem cell rescue, and differentiation therapy (93).
A recent study by Tümmler et al. (21) showed that expression
of chemerin receptors could successfully prognosticate
neuroblastoma. Based on data from public datasets, the
study found that high expression of GPR1 and CMKLR1 was
associated with low survival rates. Furthermore, expression
of CMKLR1 and CCRL2 was found to be upregulated in
neuroblastoma cohorts in comparison to benign counterparts,
while increased CCRL2 expression was correlated to poor
prognosis. Increased chemerin expression was also found
in neuroblastoma cohorts in comparison to neural crest,
though no differences in expression levels were found between
neuroblastoma and benign neurofibroma. Overall, CMKLR1 and
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non-tumor tissues found that 16 of the 20 tumor samples
exhibited a significant downregulation of chemerin. Chemerin
mRNA expression was also tested in 26 NSCLC tumor samples
along with their healthy tissue counterparts, and the RT-qPCR
results of these specimen showed that chemerin expression was
significantly reduced in most (19) of the samples. Furthermore,
chi-squared analysis of chemerin expression levels in NSCLC
specimen, distinguished between low and high based on a
mean score, found that tissue chemerin expression levels were
associated with tumor-node metastasis stage, differentiation, and
lymph node metastasis (24, 27). Both studies identified tissue
chemerin levels as an independent prognostic factor for NSCLC
and reported that, overall, higher chemerin expression was
associated with positive prognosis (24, 27).
Unlike tissue expression levels, elevated serum chemerin levels
were observed in NSCLC patients, which correlated to poorer
overall survival, and was identified as an independent risk factor
for poorer prognosis in NSCLC patients (97). In a study by Xu
et al. (97), analysis of serum samples from 189 NSCLC patients
and 120 healthy individuals revealed that serum chemerin levels
were upregulated in NSCLC patients. Furthermore, both early
stage and advanced stage NSCLC patients showed elevated levels
of chemerin in serum, with a further increase for patients
with advanced stage NSCLC. For diagnosis of NSCLC, serum
chemerin levels had a test sensitivity and specificity of 62.4%
and 67.5%, respectively. When combined with carcinoembryonic
antigen tests, the sensitivity and specificity of the test increased to
78.3 and 84.2%, respectively. Thus, serum chemerin expression
was also established as a viable biomarker for diagnosis and
prognosis of NSCLC (97).
To elucidate chemerin’s mechanistic roles in lung cancer,
Unver et al. (31) examined chemerin’s functions in Lewis lung
carcinoma (LLC), a mouse model of lung cancer. LLC cells
were genetically altered to secrete prochemerin at low levels
insufficient to induce chemotaxis. Media from the modified LLC
cells was used to culture splenic leukocytes and suppress their
expression of inflammatory cytokines, TNF-α, and IL-12 p40
(31). Results were replicated in vivo, as expression of TNF-α
and IL-12 p40 was also reduced in the prochemerin expressing
LLC tumor tissues. These observations are notable because
inflammation, though sometimes necessary for antitumor
activity, is often exploited by tumors to establish a pro-tumor
environment, particularly in cases of NSCLC (98, 99). In
syngeneic C57BL6 mice implanted with prochemerin-expressing
LLC grafts, tumor formation was impeded by prochemerin
expression (31). However, in mice with successful tumor
formation, control tumors and prochemerin expressing tumors
showed no difference in growth rate, indicating that prochemerin
expression may play a role in modulating tumorigenesis through
reduced inflammation but not in tumor suppression of LLC (31).

GPR1 expression was shown to be a potentially viable indicator
of prognosis in neuroblastoma patients (21).
According to the same study, inhibition of the
chemerin/CMKLR1 axis exhibited antitumor effects in vitro
and in vivo, suggesting that the chemerin/CMKLR1 axis could
be a potential therapeutic target for neuroblastoma. In vitro,
expression of CMKLR1, chemerin mRNA/protein, and GPR1
was verified in neuroblastoma cell lines (as well as primary
tumors) via real time-PCR and western blot analysis (21).
Exposure to inflammatory cytokines TNF-α, IL-1β, and serum
resulted in increased secretion of chemerin by neuroblastoma
cells. Moreover, the mechanistic effects of added chemerin
in neuroblastoma cell lines was the induction of intracellular
calcium, activation of MAPK and Akt signaling, and synthesis of
MMP-2. Specifically, in a human neuroblastoma cell line (SK-NSH), chemerin induced a rapid increase in intracellular calcium.
In SK-N-AS and SK-N-BE(2) cells, a dose-dependent increase in
MEK 1/2, Akt, and ERK 1/2 phosphorylation was observed upon
addition of chemerin, indicating the activation of Akt and MAPK
pathways. In the same cell lines, a dose-dependent increase in
MMP-2 synthesis was shown via real-time zymography, after
cells had been stimulated via chemerin for various timepoints.
Significantly, inhibition of CMKLR1 on four neuroblastoma cell
lines via α-NETA, a recently described CMKLR1 inhibitor (94),
dose-dependently reduced cell viability and clonogenicity (21).
Similar results were achieved in vivo. In a SK-N-AS xenograft
model, mice that were pretreated with α-NETA, before tumors
reached a specified volume, showed longer survival and delayed
tumor growth compared to control mice (21). Thus, the results
of both in vitro and in vivo experiments indicated that targeting
chemerin/CMKLR1 could potentially elicit antitumor effects in
clinical settings.

Non-small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related deaths in
the world, having a 5-year survival rate of <15% and resulting
in ∼1.4 million deaths per year (66, 95). This is despite the
fact that various chemotherapy-based treatment methods are
available to patients. For non-small cell lung cancer (NSCLC),
which accounts for the majority (∼85%) of lung cancer cases,
multiple studies indicate that chemerin may be of great diagnostic
and prognostic value (24, 27, 96). Two independent studies,
one in 2011 and another in 2016, reported that chemerin was
downregulated in NSCLC (24, 27). Zhao et al. (24) compared 108
NSCLC tumor samples with corresponding disease-free tissues
and found that 56 of the NSCLC patient tumors showed a
lower chemerin expression profile. They also found a positive
correlation between chemerin expression levels and infiltration
of NK cells into tumor, as revealed by CD56 IHC staining of
NSCLC patient tissue samples. Moreover, multivariate analysis
of various parameters, such as age, smoking history, tumor
size, and differentiation grade, and univariate analysis, together,
revealed that lower levels of chemerin expression in tissue
were significantly associated with tumor-node metastasis stage,
degree of differentiation, and poorer survival rates (24). In
line with these findings, a 2016 study by Cai et al. (27)
comparing 20 NSCLC tumor samples with their corresponding
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Prostate Cancer
Prostate cancer is one of the most frequently diagnosed cancers
in the United States, with more than 164,000 new cases per
year (100). It is also the second leading cause of cancerrelated mortality in the country (101). Treatment of prostate
cancer mainly consists of surgery and radiotherapy for localized
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tissues via qRT-PCR and IHC stains of 147 SCCOT specimen
and their associated peritumoral, healthy tissues, determined
that both chemerin mRNA and protein was upregulated in
primary SCCOT specimens (18). Significantly, overexpression of
chemerin was correlated with poor differentiation, high clinical
stage, and lymph node metastasis. Multivariate survival analysis
further showed that chemerin was an independent prognostic
factor for SCCOT and that patients with overexpressed chemerin
had a shorter cancer-related survival time (18). Though
chemerin’s role in SCCOT tumor progression is still unclear, the
results indicate that chemerin may be a therapeutic target for
inhibiting tumor growth.
Another study found that serum and salivary levels of
chemerin were also elevated in OSCC patients, indicating that
chemerin may be used to diagnose patients (113). The study
included serum and salivary samples from 15 patients with
early stage OSCC, 15 patients with oral premalignant lesions
(OPML), and 15 healthy individuals, and analysis of these
specimen showed that serum and salivary levels of chemerin, and
MMP-9, were upregulated in OSCC compared to OPML, and
in OPML compared to healthy patients. Analysis of the ROC
curve revealed that serum and salivary chemerin levels had a test
sensitivity and specificity of 100% for detecting early stage OSCC
(113).

cases and androgen deprivation therapy and chemotherapy for
metastatic cases (102).
Studies have shown that chemerin is significantly
downregulated in prostate cancer. Both analyses of public
datasets and RT-qPCR of human prostate tumor samples in
several studies demonstrated reduced expression of chemerin,
indicating that prostate tumors may downregulate chemerin as a
means of immune evasion (15, 26, 103, 104). Thus, it is possible
that therapeutic application of chemerin in prostate cancer may
enhance anti-tumor immunity and slow tumor progression.

Squamous Cell Carcinoma of the
Esophagus
Esophageal cancer affects millions of people worldwide, with
approximately half a million new cases being diagnosed each
year (105). Of those cases, esophageal squamous cell carcinoma
(ESCC) accounts for a dominant majority, 90% (105). The
outlook for patients is bleak, as esophageal cancers are among the
deadliest tumors in the world due to its fast progression and late
diagnosis (106). Standard therapy for esophageal cancer patients
consists of esophagectomy, radiotherapy, and/or chemotherapy
(106).
Identifying chemerin’s role in ESCC, kumar et al. (20) showed
that chemerin was upregulated in ESCC myofibroblasts, which
also expressed CMKLR1 (20). Moreover, chemerin was shown to
increase invasiveness of ESCC in vitro, which was mediated by
the accumulation of MMP-1, MMP-2, and MMP-3. In Boyden
chambers, chemerin stimulated the migration and invasion
of OE21 cells, a human ESCC cell line, and this effect was
inhibited by antagonists of CMKLR1 and chemerin siRNA,
supporting previous results. Analysis of the OE21 media showed
that there was increased expression of MMP-1, MMP-2, and
MMP-3, and this effect could be reduced by inhibiting p44/42
MAPK kinase and protein kinase C, showing that they were
responsible for increased MMP expression levels (20). Combined
with previous reports that MMP-1 expression is associated with
poor prognosis in esophageal cancer, the study suggested that
chemerin could elicit pro-tumor effects in ESCC (107–109).
Thus, it was postulated that targeting chemerin/CMKLR1 may
be a viable therapeutic approach for ESCC.

Squamous Cell Carcinoma of the Skin
Cutaneous Squamous Cell Carcinoma (CSCC) is the second
most prevalent form of skin cancer in the world (114). Affecting
the elderly at disproportionately higher rates, CSCC is mainly
caused by chronic exposure to ultraviolet radiation (114, 115).
Fortunately, advances in treatment have made new, targeted
molecular therapies available to patients, in addition to the
standard options of surgery and chemotherapy (116).
A recent study indicated that chemerin may contribute
to CSCC cell migration and tumor growth. The study by
Farsam et al. (19) found that chemerin was downregulated
in CSCC but upregulated in senescent fibroblasts and skin
samples of elderly patients (19, 117). Transcriptional analysis
of CCRL2 in CSCC cell lines further revealed that CCRL2
expression was significantly increased on CSCC tumor cells
in vitro, and enhanced tumor cell migration was observed as
a result of increased levels of senescence-associated chemerin,
which was abrogated by inhibition of chemerin in senescent
fibroblasts. Moreover, CMKLR1, or the combination of CCRL2
and GPR1, was necessary for CSCC cell migration via chemerin,
given that suppression of either one of the receptors reversed
these effects. Finally, chemerin was shown to activate MAPK
signaling in SCL-1 cells, a human CSCC cell line, with high
expression of CCRL2 and low expression of GPR1. Specifically,
the JNK and ERK 1/2 pathways were indicated as the primary
mediators of chemerin-mediated effects in CSCC tumor cells, as
inhibition of these pathways neutralized the previously observed
migratory response. Taken together, these results showed that
chemerin enhanced CSCC cell migration and promoted tumor
growth through chemerin/CMKLR1/CCRL2/GPR1 interactions
and subsequent activation of MAPK pathway subtypes (19).

Squamous Cell Carcinoma of the Oral
Tongue
Squamous cell carcinoma of the oral tongue (SCCOT) is the most
common form of oral squamous cell carcinoma (OSCC), which
has a worldwide incidence rate of ∼6.6 cases per 100,000 males
and 2.9 cases per 100,000 females (110). Current treatment for
SCCOT ranges from surgery alone, for stage 1 and 2 cases, to
a combination of surgery and radiotherapy for later stages of
disease (111). Though early diagnosis and treatment methods are
currently available, the primary causes of mortality in SCCOT
patients are lymph node metastasis and recurrence (112). Thus,
biomarkers for those parameters may be of great prognostic value
for SCCOT patients.
A study by Wang et al. (18), looking at chemerin mRNA
expression in 19 SCCOT tumor tissues and matched adjacent
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CONCLUSION

prognostic value have also been evaluated in a few cancer types.
Given the efficacy of chemerin-mediated anti-tumor responses
seen now in several tumor settings, future research investigating
chemerin’s roles in additional tumor types is warranted, with
a particular focus on manifesting its therapeutic potential for
cancer treatment. Importantly, it should be noted that chemerinbased treatments may add to the efficacy of approved checkpoint
inhibitors, as they likely act through independent mechanisms to
diminish tumor growth.

Chemerin is a versatile protein with significant functions in
modulating tumor growth. With altered expression profiles
in a variety of cancer types, it can have context dependent
effects on tumorigenesis and tumor progression. In some
cases, cancers may silence RARRES2 via hypermethylation
to evade immune surveillance. In others, host systems may
increase chemerin expression as a defensive measure, recruiting
antitumor immunocytes, reducing secretion of inflammatory
cytokines, and/or modifying signaling pathways. Through both
immune-independent and immune-dependent mechanisms,
chemerin has been shown to elicit tumor-suppressive effects
in various cancers, and there is a strong possibility that the
mechanisms of tumor inhibition seen in these tumor types
may be replicated in others as well. Importantly, for cases in
which silencing of RARRES2 has been reported, the restoration
and/or forced overexpression of chemerin in the microtumor
environment may incite compelling antitumor effects, indicating
new avenues of research for chemerin in cancer.
Here, we have comprehensively reviewed the current data
on chemerin’s functions in cancer, along with its underlying
mechanisms when available. Concentrating on aspects that
may lead to clinical applications, chemerin’s diagnostic and/or
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